HRS-4729 Injection Placebo

DRUG3 trials

Sponsors

Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Overweight or Obesity

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects

CompletedNCT06762600

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2025-01-16End: 2026-03-12Updated: 2026-04-30

Phase 2

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

Not yet recruitingNCT07660848

Fujian Shengdi Pharmaceutical Co., Ltd.Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Start: 2026-07-01End: 2028-07-01Target: 160Updated: 2026-06-22

A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

Not yet recruitingNCT07690826

Fujian Shengdi Pharmaceutical Co., Ltd.Overweight or Obesity

Start: 2026-07-01End: 2027-07-01Target: 252Updated: 2026-07-08